A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 16 Sep 2016 Results assessing the effect of semaglutide on hypoglycaemic counter-regulation, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 25 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.